Первый опыт применения комбинации брентуксимаба ведотина с интенсивной химиотерапией у первичной больной анапластической крупноклеточной лимфомой: обзор литературы и описание клинического случая - Журнал Терапевтический архив № 7 Вопросы гематологии 2018
Первый опыт применения комбинации брентуксимаба ведотина с интенсивной химиотерапией у первичной больной анапластической крупноклеточной лимфомой: обзор литературы и описание клинического случая
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Нодальная анапластическая крупноклеточная лимфома, ALK-негативная (нАККЛ, ALK-) – Т-клеточная лимфома, характеризуется агрессивным клиническим течением и низкой химиочувствительностью к СНОР (циклофосфамид, доксорубицин, винкристин, преднизолон) и подобным программам. В статье представлен обзор литературы и описано собственное клиническое наблюдение нАККЛ, ALK-. Впервые в качестве терапии первой линии применена комбинация брентуксимаба ведотина с модифицированной программой NHL-BFM-90. Получен полный противоопухолевый ответ, для консолидации которого выполнена высокодозная химиотерапия с последующей трансплантацией аутологичных стволовых клеток крови. Выбранная тактика лечения позволила достигнуть полной ремиссии заболевания у больной из группы промежуточного риска.
Ключевые слова: брентуксимаб ведотин, анапластическая крупноклеточная лимфома, ALK-негативная, модифицированная программа NHL-BFM-90, высокодозная химиотерапия, трансплантация аутологичных стволовых клеток крови.
For the first time a combination of Brentuximab vedotin with modified program NHL-BFM-90 was used as a first-line therapy. As a result of immunochemotherapy a complete antineoplastic effect was obtained. For consolidation of this effect high-dose chemotherapy with following autologous blood stem cell transplantation was performed. The chosen treatment tactics allowed to achieve a complete remission in a medium risk group patient.
Keywords: Brentuximab vedotin, anaplastic large cell lymphoma, ALK-negative, modified program NHL-BFM-90, high-dose chemotherapy, autologous blood stem cell transplantation.
Ключевые слова: брентуксимаб ведотин, анапластическая крупноклеточная лимфома, ALK-негативная, модифицированная программа NHL-BFM-90, высокодозная химиотерапия, трансплантация аутологичных стволовых клеток крови.
________________________________________________
For the first time a combination of Brentuximab vedotin with modified program NHL-BFM-90 was used as a first-line therapy. As a result of immunochemotherapy a complete antineoplastic effect was obtained. For consolidation of this effect high-dose chemotherapy with following autologous blood stem cell transplantation was performed. The chosen treatment tactics allowed to achieve a complete remission in a medium risk group patient.
Keywords: Brentuximab vedotin, anaplastic large cell lymphoma, ALK-negative, modified program NHL-BFM-90, high-dose chemotherapy, autologous blood stem cell transplantation.
Список литературы
1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC, 2017: 418-421.
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.International T-Cell Lymphoma Project. J Clin Oncol. 2008 (Sep 1); 26(25): 4124-30. https://doi: 10.1200/JCO.2008.16.4558
3. Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000 (Dec 1); 96(12):3681-95.
4. Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol. 2001( Sep); 114(4):741-60.
5. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999 (Apr 15); 93(8):2697-706.
6. Ковригина А.М., Пробатова Н.А. Лимфома Ходжкина и крупноклеточные лимфомы. Монография. М.: Издательство "Медицинское информационное агентство", 2007. [Kovrigina AM, Probatova NA. Hodgkin lymphoma and large cell lymphomas. Monografija. M.: Izdatel'stvo "Medicinskoe informacionnoe agentstvo", 2007. (In Russ.)].
7. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014 (Aug 28); 124(9):1473-80. https://doi: 10.1182/blood-2014-04-571091
8. Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, Schmitt-Graeff A, Herling M, Amin HM, Lai R. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res. 2003; 9(10 Pt 1): 3692-3699.
9. Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE Piva R, Bertoni F, Rabadan R, Inghirami G. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015; 27:516-532. https://doi: 10.1016/j.ccell.2015.03.006
10. Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017( Jul); 31(7):1633-1637. https://doi: 10.1038/leu. 2017.103
11. Виноградова Ю.Е., Луценко И.Н., Капланская И.Б., Воробьев И.А., Самойлова Р.С., Горгидзе Л.А., Рыжикова Н.В., Валиев Т.Т., Гилязитдинова Е.А., Джулакян У.Л., Егорова Е.К., Звонков Е.Е., Красильникова Б.Б., Магомедова А.У., Марголин О.В., Марьин Д.С., Кременецкая А.М., Кравченко С.К., Воробьев А.И. Эффективность терапии различных вариантов анаплазированных Т-крупноклеточных лимфом. Терапевтический архив. 2008; 80(7): 33-37. [Vinogradova JE, Lucenko IN, Kaplanskaja IB, Vorob'ev IA, Samojlova RS, Gorgidze LA, Ryzhikova NV, Valiev TT, Giljazitdinova EA, Dzhulakjan UL, Egorova EK, Zvonkov EE, Krasil'nikova BB, Magomedova AU, Margolin OV, Mar'in DS, Kremeneckaja AM, Kravchenko SK, Vorob'ev AI. Efficacy of therapy of different variants of anaplastic large t-cell lymphomas. Terapevticheskij arhiv. 2008; 80 (7): 33-37. (In Russ.)].
12. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD. International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008 (Jun 15); 111(12):5496-504. https://doi: 10.1182/blood-2008-01-134270
13. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010 (Nov 4); 116(18): 3418-25. https://doi: 10.1182/blood-2010-02-270785
14. d'Amore F, Relander T, Lauritzsen G.F, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012 (Sep 1); 30(25):3093-9. https://doi: 10.1200/JCO. 2011.40.2719
15. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM, Savage KJ. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. Clin Oncol. 2013 (Jun 1); 31(16):1970-6. https://doi: 10.1200/JCO.2012.44.7524
16. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2005 (Nov); 46(11):1569-73. https://doi: 10.1080/10428190500217312
17. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 (Nov 4); 363(19):1812-21. https://doi: 10.1056/NEJMoa1002965
18. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM., Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017 (Dec 21); 130(25): 2709-2717. https://doi: 10.1182/blood-2017-05-780049
19. Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014 (Mar 19); 7:24. https://doi: 10.1186/1756-8722-7-24
20. Abid MB, Wang S, Loi HY, Poon LM. ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. Ann Hematol. 2016 (Oct); 95(10):1725-6. https://doi: 10.1007/s00277-016-2746-3
21. Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, Curry JL, Miranda RN, Duvic M, Prieto VG, Aung PP. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016 (Dec); 43(12):1161-1166. https://doi: 10.1111/cup.12797
22. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
J Clin Oncol. 2014 (Oct 1); 32(28): 3137-43. https://doi: 10.1200/JCO. 2013.54.2456
23. A Comparison of Brentuximab Vedotin and CHP with Standard-of-care CHOP in the Treatment of Patients with CD30-positive Mature T-cell Lymphomas (ECHELON-2). ClinicalTrials.gov Identifier: NCT01777152.
24. Программное лечение заболеваний системы крови: сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.: Издательство “Практика”, 2012. [Software treatment of blood system diseases. Pod red. V.G.Savchenko. M.: Izdatel'stvo “Praktika”, 2012. (In Russ.)].
25. Горенкова Л.Г., Кравченко С.К. Результаты и перспективы лечения анапластической крупноклеточной лимфомы у взрослых пациентов. Гематология и трансфузиология. 2016; 61: 14. [Gorenkova LG, Kravchenko SK. Results and perspectives of treatment anaplastic large cell lymphoma in adults. Gematologija i transfuziologija. 2016; 61: 14. (In Russ.)].
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.International T-Cell Lymphoma Project. J Clin Oncol. 2008 (Sep 1); 26(25): 4124-30. https://doi: 10.1200/JCO.2008.16.4558
3. Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000 (Dec 1); 96(12):3681-95.
4. Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol. 2001( Sep); 114(4):741-60.
5. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999 (Apr 15); 93(8):2697-706.
6.[Kovrigina AM, Probatova NA. Hodgkin lymphoma and large cell lymphomas. Monografija. M.: Izdatel'stvo "Medicinskoe informacionnoe agentstvo", 2007. (In Russ.)].
7. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014 (Aug 28); 124(9):1473-80. https://doi: 10.1182/blood-2014-04-571091
8. Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, Schmitt-Graeff A, Herling M, Amin HM, Lai R. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res. 2003; 9(10 Pt 1): 3692-3699.
9. Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE Piva R, Bertoni F, Rabadan R, Inghirami G. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015; 27:516-532. https://doi: 10.1016/j.ccell.2015.03.006
10. Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017( Jul); 31(7):1633-1637. https://doi: 10.1038/leu. 2017.103
11. Виноградова Ю.Е., Луценко И.Н., Капланская И.Б., Воробьев И.А., Самойлова Р.С., [Vinogradova JE, Lucenko IN, Kaplanskaja IB, Vorob'ev IA, Samojlova RS, Gorgidze LA, Ryzhikova NV, Valiev TT, Giljazitdinova EA, Dzhulakjan UL, Egorova EK, Zvonkov EE, Krasil'nikova BB, Magomedova AU, Margolin OV, Mar'in DS, Kremeneckaja AM, Kravchenko SK, Vorob'ev AI. Efficacy of therapy of different variants of anaplastic large t-cell lymphomas. Terapevticheskij arhiv. 2008; 80 (7): 33-37. (In Russ.)].
12. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD. International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008 (Jun 15); 111(12):5496-504. https://doi: 10.1182/blood-2008-01-134270
13. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010 (Nov 4); 116(18): 3418-25. https://doi: 10.1182/blood-2010-02-270785
14. d'Amore F, Relander T, Lauritzsen G.F, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012 (Sep 1); 30(25):3093-9. https://doi: 10.1200/JCO. 2011.40.2719
15. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM, Savage KJ. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. Clin Oncol. 2013 (Jun 1); 31(16):1970-6. https://doi: 10.1200/JCO.2012.44.7524
16. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2005 (Nov); 46(11):1569-73. https://doi: 10.1080/10428190500217312
17. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 (Nov 4); 363(19):1812-21. https://doi: 10.1056/NEJMoa1002965
18. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM., Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017 (Dec 21); 130(25): 2709-2717. https://doi: 10.1182/blood-2017-05-780049
19. Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014 (Mar 19); 7:24. https://doi: 10.1186/1756-8722-7-24
20. Abid MB, Wang S, Loi HY, Poon LM. ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. Ann Hematol. 2016 (Oct); 95(10):1725-6. https://doi: 10.1007/s00277-016-2746-3
21. Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, Curry JL, Miranda RN, Duvic M, Prieto VG, Aung PP. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016 (Dec); 43(12):1161-1166. https://doi: 10.1111/cup.12797
22. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
J Clin Oncol. 2014 (Oct 1); 32(28): 3137-43. https://doi: 10.1200/JCO. 2013.54.2456
23. A Comparison of Brentuximab Vedotin and CHP with Standard-of-care CHOP in the Treatment of Patients with CD30-positive Mature T-cell Lymphomas (ECHELON-2). ClinicalTrials.gov Identifier: NCT01777152.
24. [Software treatment of blood system diseases. Pod red. V.G.Savchenko. M.: Izdatel'stvo “Praktika”, 2012. (In Russ.)].
25. [Gorenkova LG, Kravchenko SK. Results and perspectives of treatment anaplastic large cell lymphoma in adults. Gematologija i transfuziologija. 2016; 61: 14. (In Russ.)].
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.International T-Cell Lymphoma Project. J Clin Oncol. 2008 (Sep 1); 26(25): 4124-30. https://doi: 10.1200/JCO.2008.16.4558
3. Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000 (Dec 1); 96(12):3681-95.
4. Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol. 2001( Sep); 114(4):741-60.
5. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999 (Apr 15); 93(8):2697-706.
6. Ковригина А.М., Пробатова Н.А. Лимфома Ходжкина и крупноклеточные лимфомы. Монография. М.: Издательство "Медицинское информационное агентство", 2007. [Kovrigina AM, Probatova NA. Hodgkin lymphoma and large cell lymphomas. Monografija. M.: Izdatel'stvo "Medicinskoe informacionnoe agentstvo", 2007. (In Russ.)].
7. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014 (Aug 28); 124(9):1473-80. https://doi: 10.1182/blood-2014-04-571091
8. Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, Schmitt-Graeff A, Herling M, Amin HM, Lai R. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res. 2003; 9(10 Pt 1): 3692-3699.
9. Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE Piva R, Bertoni F, Rabadan R, Inghirami G. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015; 27:516-532. https://doi: 10.1016/j.ccell.2015.03.006
10. Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017( Jul); 31(7):1633-1637. https://doi: 10.1038/leu. 2017.103
11. Виноградова Ю.Е., Луценко И.Н., Капланская И.Б., Воробьев И.А., Самойлова Р.С., Горгидзе Л.А., Рыжикова Н.В., Валиев Т.Т., Гилязитдинова Е.А., Джулакян У.Л., Егорова Е.К., Звонков Е.Е., Красильникова Б.Б., Магомедова А.У., Марголин О.В., Марьин Д.С., Кременецкая А.М., Кравченко С.К., Воробьев А.И. Эффективность терапии различных вариантов анаплазированных Т-крупноклеточных лимфом. Терапевтический архив. 2008; 80(7): 33-37. [Vinogradova JE, Lucenko IN, Kaplanskaja IB, Vorob'ev IA, Samojlova RS, Gorgidze LA, Ryzhikova NV, Valiev TT, Giljazitdinova EA, Dzhulakjan UL, Egorova EK, Zvonkov EE, Krasil'nikova BB, Magomedova AU, Margolin OV, Mar'in DS, Kremeneckaja AM, Kravchenko SK, Vorob'ev AI. Efficacy of therapy of different variants of anaplastic large t-cell lymphomas. Terapevticheskij arhiv. 2008; 80 (7): 33-37. (In Russ.)].
12. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD. International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008 (Jun 15); 111(12):5496-504. https://doi: 10.1182/blood-2008-01-134270
13. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010 (Nov 4); 116(18): 3418-25. https://doi: 10.1182/blood-2010-02-270785
14. d'Amore F, Relander T, Lauritzsen G.F, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012 (Sep 1); 30(25):3093-9. https://doi: 10.1200/JCO. 2011.40.2719
15. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM, Savage KJ. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. Clin Oncol. 2013 (Jun 1); 31(16):1970-6. https://doi: 10.1200/JCO.2012.44.7524
16. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2005 (Nov); 46(11):1569-73. https://doi: 10.1080/10428190500217312
17. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 (Nov 4); 363(19):1812-21. https://doi: 10.1056/NEJMoa1002965
18. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM., Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017 (Dec 21); 130(25): 2709-2717. https://doi: 10.1182/blood-2017-05-780049
19. Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014 (Mar 19); 7:24. https://doi: 10.1186/1756-8722-7-24
20. Abid MB, Wang S, Loi HY, Poon LM. ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. Ann Hematol. 2016 (Oct); 95(10):1725-6. https://doi: 10.1007/s00277-016-2746-3
21. Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, Curry JL, Miranda RN, Duvic M, Prieto VG, Aung PP. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016 (Dec); 43(12):1161-1166. https://doi: 10.1111/cup.12797
22. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
J Clin Oncol. 2014 (Oct 1); 32(28): 3137-43. https://doi: 10.1200/JCO. 2013.54.2456
23. A Comparison of Brentuximab Vedotin and CHP with Standard-of-care CHOP in the Treatment of Patients with CD30-positive Mature T-cell Lymphomas (ECHELON-2). ClinicalTrials.gov Identifier: NCT01777152.
24. Программное лечение заболеваний системы крови: сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.: Издательство “Практика”, 2012. [Software treatment of blood system diseases. Pod red. V.G.Savchenko. M.: Izdatel'stvo “Praktika”, 2012. (In Russ.)].
25. Горенкова Л.Г., Кравченко С.К. Результаты и перспективы лечения анапластической крупноклеточной лимфомы у взрослых пациентов. Гематология и трансфузиология. 2016; 61: 14. [Gorenkova LG, Kravchenko SK. Results and perspectives of treatment anaplastic large cell lymphoma in adults. Gematologija i transfuziologija. 2016; 61: 14. (In Russ.)].
________________________________________________
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.International T-Cell Lymphoma Project. J Clin Oncol. 2008 (Sep 1); 26(25): 4124-30. https://doi: 10.1200/JCO.2008.16.4558
3. Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000 (Dec 1); 96(12):3681-95.
4. Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol. 2001( Sep); 114(4):741-60.
5. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999 (Apr 15); 93(8):2697-706.
6.[Kovrigina AM, Probatova NA. Hodgkin lymphoma and large cell lymphomas. Monografija. M.: Izdatel'stvo "Medicinskoe informacionnoe agentstvo", 2007. (In Russ.)].
7. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014 (Aug 28); 124(9):1473-80. https://doi: 10.1182/blood-2014-04-571091
8. Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, Schmitt-Graeff A, Herling M, Amin HM, Lai R. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res. 2003; 9(10 Pt 1): 3692-3699.
9. Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE Piva R, Bertoni F, Rabadan R, Inghirami G. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015; 27:516-532. https://doi: 10.1016/j.ccell.2015.03.006
10. Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017( Jul); 31(7):1633-1637. https://doi: 10.1038/leu. 2017.103
11. Виноградова Ю.Е., Луценко И.Н., Капланская И.Б., Воробьев И.А., Самойлова Р.С., [Vinogradova JE, Lucenko IN, Kaplanskaja IB, Vorob'ev IA, Samojlova RS, Gorgidze LA, Ryzhikova NV, Valiev TT, Giljazitdinova EA, Dzhulakjan UL, Egorova EK, Zvonkov EE, Krasil'nikova BB, Magomedova AU, Margolin OV, Mar'in DS, Kremeneckaja AM, Kravchenko SK, Vorob'ev AI. Efficacy of therapy of different variants of anaplastic large t-cell lymphomas. Terapevticheskij arhiv. 2008; 80 (7): 33-37. (In Russ.)].
12. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD. International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008 (Jun 15); 111(12):5496-504. https://doi: 10.1182/blood-2008-01-134270
13. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010 (Nov 4); 116(18): 3418-25. https://doi: 10.1182/blood-2010-02-270785
14. d'Amore F, Relander T, Lauritzsen G.F, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012 (Sep 1); 30(25):3093-9. https://doi: 10.1200/JCO. 2011.40.2719
15. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM, Savage KJ. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. Clin Oncol. 2013 (Jun 1); 31(16):1970-6. https://doi: 10.1200/JCO.2012.44.7524
16. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2005 (Nov); 46(11):1569-73. https://doi: 10.1080/10428190500217312
17. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 (Nov 4); 363(19):1812-21. https://doi: 10.1056/NEJMoa1002965
18. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM., Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017 (Dec 21); 130(25): 2709-2717. https://doi: 10.1182/blood-2017-05-780049
19. Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014 (Mar 19); 7:24. https://doi: 10.1186/1756-8722-7-24
20. Abid MB, Wang S, Loi HY, Poon LM. ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. Ann Hematol. 2016 (Oct); 95(10):1725-6. https://doi: 10.1007/s00277-016-2746-3
21. Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, Curry JL, Miranda RN, Duvic M, Prieto VG, Aung PP. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016 (Dec); 43(12):1161-1166. https://doi: 10.1111/cup.12797
22. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
J Clin Oncol. 2014 (Oct 1); 32(28): 3137-43. https://doi: 10.1200/JCO. 2013.54.2456
23. A Comparison of Brentuximab Vedotin and CHP with Standard-of-care CHOP in the Treatment of Patients with CD30-positive Mature T-cell Lymphomas (ECHELON-2). ClinicalTrials.gov Identifier: NCT01777152.
24. [Software treatment of blood system diseases. Pod red. V.G.Savchenko. M.: Izdatel'stvo “Praktika”, 2012. (In Russ.)].
25. [Gorenkova LG, Kravchenko SK. Results and perspectives of treatment anaplastic large cell lymphoma in adults. Gematologija i transfuziologija. 2016; 61: 14. (In Russ.)].
Авторы
Н.Г. ЧЕРНОВА, Е.Е. ЗВОНКОВ, Д.С. БАДМАЖАПОВА, М.Н. СИНИЦЫНА, Л.А. ГРЕБЕНЮК, Ю.В. СИДОРОВА, И.Э. КОСТИНА, А.М. КОВРИГИНА, Т.Н. ОБУХОВА, А.Б. СУДАРИКОВ, В.Г. САВЧЕНКО
ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, отделение интенсивной химиотерапии лимфом, Москва, Россия
Lymphoma intensive chemotherapy department, National Research Center for Hematology, Russian Federation, Moscow, Russia
ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, отделение интенсивной химиотерапии лимфом, Москва, Россия
________________________________________________
Lymphoma intensive chemotherapy department, National Research Center for Hematology, Russian Federation, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.